This year’s summit highlights moderate-to-severe, chronic inflammatory skin conditions and their need for incorporating the patient perspective from clinical trials to drug development for the best-in-class therapies. It focuses on genetic discoveries, antibody drug development, delivery strategies, and predictive and diagnostic technologies for safe and effective drug development.

In addition, the summit added two new tracks: Track A focusing on diseases targeting IL-4, IL-13, & IL-31, and Track B focusing on IL-17, rare diseases, and other autoimmune conditions. SCARLETRED’s CEO, Harald Schnidar, Ph.D., MBA, is invited as an expert speaker and will present our latest clinical validation and study results of our imaging and analysis technology Scarletred®Vision in Rosacea and Hidradenitis Suppurativa.

Register online and check out the complete event Guide on the homepage of the 6th Dermatology Drug Development Summit.

Use the code SPK10 to get 10% off your tickets.